Autacoids 

Introduction

Autacoids are locally acting hormones that have brief duration of action and act near their site of synthesis. They are involved in many physiological and pathological processes including inflammation, allergy, and smooth muscle function.

Categories of Autacoids

1. Biogenic Amines

   • Histamine

   • Serotonin (5-HT)

2. Polypeptides

   • Bradykinin

   • Kallidin

3. Lipid-Derived Autacoids

   • Prostaglandins

   • Leukotrienes

   • Thromboxanes

Histamine

Synthesis & Storage

• Synthesized from histidine by histidine decarboxylase.

• Stored in mast cells, basophils, and certain neurons.

Receptors

• H1: Smooth muscle, endothelium, CNS (vasodilation, bronchoconstriction, wakefulness).

• H2: Gastric parietal cells (stimulates acid secretion).

• H3: Presynaptic CNS receptors (inhibit neurotransmitter release).

• H4: Hematopoietic cells (immune modulation).

Pharmacological Actions

• Vasodilation (H1, H2)

• Increased vascular permeability

• Bronchoconstriction

• Gastric acid secretion

• Pain and itching (via H1)

Antihistamines

• H1 antagonists: Diphenhydramine, Loratadine

• H2 antagonists: Ranitidine, Famotidine

Serotonin (5-HT)

Synthesis

• Derived from tryptophan

• Found in platelets, GI tract, CNS

Receptors

• Multiple receptor types: 5-HT1 to 5-HT7

• Diverse actions including vasoconstriction, platelet aggregation, and mood regulation

Pharmacological Actions

• CNS: Mood, appetite, sleep

• GI: Peristalsis

• Platelets: Aggregation

• CVS: Vasoconstriction

Drugs Affecting 5-HT

• Agonists: Triptans (used in migraine)

• Antagonists: Ondansetron (antiemetic), Cyproheptadine

Kinins (Bradykinin & Kallidin)

Origin

• Derived from kininogens via kallikrein enzyme.

Actions

• Vasodilation

• Increased vascular permeability

• Pain production

• Smooth muscle contraction (bronchoconstriction)

Role in Pathology

• Involved in inflammation and allergic reactions

Prostaglandins (PGs) and Related Compounds

Synthesis

• Arachidonic acid → via cyclooxygenase (COX) enzymes → PGs, thromboxanes

Types and Actions

• PGE2: Vasodilation, fever, pain

• PGF2α: Uterine contraction

• PGI2 (Prostacyclin): Vasodilation, inhibits platelet aggregation

• TXA2 (Thromboxane A2): Vasoconstriction, promotes platelet aggregation

Drugs

• NSAIDs: Inhibit COX, reducing PG synthesis

• Prostaglandin analogs: Misoprostol, Latanoprost

Leukotrienes (LTs)

Synthesis

• Arachidonic acid → via lipoxygenase → Leukotrienes

Actions

• Bronchoconstriction

• Increased mucus secretion

• Attract immune cells (chemotaxis)

Clinical Relevance

• Major role in asthma and allergic rhinitis

Drugs

• LT receptor antagonists: Montelukast, Zafirlukast

• 5-LO inhibitors: Zileuton

Clinical Applications

• Allergy: Antihistamines, leukotriene antagonists

• Inflammation: NSAIDs

• Asthma: Leukotriene inhibitors

• Peptic ulcers: H2 blockers

• Migraine: 5-HT agonists (Triptans)

  Multiple Choice Questions (MCQs)

  1. Which of the following histamine receptors is primarily involved in CNS autoregulation and neurotransmitter inhibition?
  A. H1
  B. H2
  C. H3
  D. H4

  2. The dry cough observed in patients taking ACE inhibitors is primarily due to accumulation of:
  A. Histamine
  B. Serotonin
  C. Bradykinin
  D. Prostaglandin D2

  3. 5-HT1B/1D agonists (like sumatriptan) relieve migraines by:
  A. Increasing serotonin synthesis
  B. Inhibiting platelet aggregation
  C. Inducing vasoconstriction of cranial blood vessels
  D. Blocking serotonin reuptake

  4. Which of the following eicosanoids is most responsible for uterine contraction?
  A. PGE2
  B. PGF2α
  C. PGI2
  D. TXA2

  5. The primary site of serotonin synthesis in the body is:
  A. Brainstem raphe nuclei
  B. Platelets
  C. Adrenal cortex
  D. Enterochromaffin cells in the GI tract

  6. Leukotriene receptor antagonists are most useful in the treatment of:
  A. Gastric ulcer
  B. Rheumatoid arthritis
  C. Asthma
  D. Depression

  7. Which prostaglandin is cytoprotective to gastric mucosa and can be used to prevent NSAID-induced ulcers?
  A. PGF2α
  B. PGE1 analog (e.g., misoprostol)
  C. TXA2
  D. LTB4

  8. Which of the following is a selective COX-2 inhibitor?
  A. Ibuprofen
  B. Aspirin
  C. Naproxen
  D. Celecoxib

  9. The H4 histamine receptor plays a major role in:
  A. Vasodilation
  B. Acid secretion
  C. Immune cell chemotaxis
  D. Sleep regulation

  10. Which of the following drugs is a 5-LOX inhibitor?
  A. Montelukast
  B. Zileuton
  C. Zafirlukast
  D. Misoprostol

  Answer Key – MCQs

  1. C. H3

  2. C. Bradykinin

  3. C. Inducing vasoconstriction of cranial blood vessels

  4. B. PGF2α

  5. D. Enterochromaffin cells in the GI tract

  6. C. Asthma

  7. B. PGE1 analog (e.g., misoprostol)

  8. D. Celecoxib

  9. C. Immune cell chemotaxis

  10. B. Zileuton

  Essay 

  ---

  1. Discuss the role of the kinin–kallikrein system in inflammation and how ACE inhibitors impact this pathway.

  The kinin–kallikrein system is a proteolytic cascade that generates bioactive peptides known as kinins, notably bradykinin and kallidin, from plasma precursors (kininogens) through the action of kallikreins.

  Bradykinin is a potent vasodilator, increases vascular permeability, and induces pain by sensitizing sensory nerves. It acts primarily via B2 receptors (constitutive) and B1 receptors (induced during inflammation). Upon activation, bradykinin stimulates nitric oxide (NO) and prostaglandin production, enhancing inflammation.

  Angiotensin-Converting Enzyme (ACE), also known as kininase II, degrades bradykinin. Thus, ACE inhibitors (e.g., enalapril) used in treating hypertension and heart failure, inadvertently increase bradykinin levels. This accounts for some of their beneficial vasodilatory effects but also explains common side effects like dry cough and angioedema.

  In summary, the kinin–kallikrein system is central to inflammatory signaling and vascular tone regulation. ACE inhibition accentuates bradykinin activity, contributing both to therapeutic effects and adverse reactions.

  ---

  2. Explain the biosynthesis of eicosanoids from arachidonic acid and the pharmacological significance of targeting COX and LOX enzymes.

  Eicosanoids are derived from arachidonic acid, a 20-carbon polyunsaturated fatty acid released from membrane phospholipids via phospholipase A2. It undergoes enzymatic conversion by two major pathways:

  • Cyclooxygenase (COX) → Produces prostaglandins (PGs), thromboxanes (TXs)

  • Lipoxygenase (LOX) → Produces leukotrienes (LTs)

  COX enzymes exist in two isoforms:

  • COX-1: Constitutive; involved in physiological functions like gastric cytoprotection and platelet function

  • COX-2: Inducible; upregulated in inflammation and cancer

  LOX enzymes, particularly 5-LOX, catalyze the formation of leukotrienes, which are crucial in asthma, allergic rhinitis, and inflammation.

  Pharmacological targeting:

  • NSAIDs inhibit COX enzymes, reducing pain, fever, and inflammation. However, non-selective inhibition can cause gastric ulcers.

  • COX-2 selective inhibitors (e.g., celecoxib) reduce inflammation with fewer GI side effects but may increase cardiovascular risks.

  • Leukotriene receptor antagonists (e.g., montelukast) and 5-LOX inhibitors (e.g., zileuton) are used in asthma and allergies.

  Thus, targeting these pathways enables precision treatment in inflammatory, cardiovascular, and allergic conditions.

  ---

  3. Describe the classification of serotonin receptors and the rationale for pharmacological modulation in clinical practice.

  Serotonin (5-HT) receptors are classified into seven major families (5-HT1 to 5-HT7), encompassing at least 14 subtypes. All are G protein-coupled receptors (GPCRs), except 5-HT3, which is a ligand-gated ion channel.

  • 5-HT1 (A, B, D): Inhibitory, Gi-coupled – regulate vasoconstriction and CNS neurotransmission

  • 5-HT2 (A, B, C): Excitatory, Gq-coupled – affect smooth muscle, platelet aggregation, CNS activity

  • 5-HT3: Ligand-gated cation channel – involved in nausea and vomiting reflex

  • 5-HT4/6/7: Gs-coupled – involved in GI motility and circadian rhythms

  Pharmacological significance:

  • 5-HT1B/1D agonists (triptans) → used in migraine to cause cranial vasoconstriction

  • 5-HT3 antagonists (ondansetron) → antiemetics in chemotherapy

  • SSRIs (fluoxetine) → block serotonin reuptake for depression and anxiety

  • Cyproheptadine → 5-HT2 antagonist used in serotonin syndrome

  Hence, modulation of different receptor subtypes allows targeted interventions across neurology, psychiatry, gastroenterology, and oncology.

  ---

  4. Evaluate the therapeutic use of autacoid modulators in managing asthma, highlighting both leukotriene and prostaglandin pathways.

  Asthma is a chronic inflammatory airway disease involving immune cell activation, bronchoconstriction, and mucus production. Autacoids, particularly leukotrienes and prostaglandins, are central to its pathophysiology.

  • Leukotrienes (C4, D4, E4) cause bronchoconstriction, increased vascular permeability, and eosinophil recruitment.

  • Prostaglandins (PGD2, PGF2α) contribute to bronchial inflammation and bronchial smooth muscle contraction.

  Therapeutic modulation:

  • Leukotriene receptor antagonists (e.g., montelukast, zafirlukast): Block CysLT1 receptors to reduce bronchoconstriction and inflammation.

  • 5-LOX inhibitors (e.g., zileuton): Prevent leukotriene synthesis.

  • Prostaglandin pathway inhibitors (NSAIDs) are generally avoided due to risk of exacerbation in NSAID-exacerbated respiratory disease (NERD).

  • Biologics (e.g., dupilumab): Target upstream mediators (IL-4, IL-13) influencing autacoid production.

  Overall, leukotriene antagonists are integral in mild-to-moderate asthma management, particularly in aspirin-sensitive and exercise-induced asthma.

  ---

  5. Analyze the emerging roles of H3 and H4 histamine receptors in neurological and immunological disorders, respectively.

  H3 receptors are predominantly expressed in the CNS, functioning as autoreceptors and heteroreceptors, modulating the release of histamine, dopamine, acetylcholine, and norepinephrine. They are coupled to Gi proteins and inhibit neurotransmitter release.

  Emerging roles:

  • Cognitive dysfunction (e.g., Alzheimer’s disease)

  • Narcolepsy and sleep disorders

  • Schizophrenia and ADHD

  H4 receptors, found on bone marrow, eosinophils, mast cells, and dendritic cells, are also Gi-coupled and play key roles in chemotaxis, cytokine release, and immune regulation.

  Emerging roles:

  • Allergic inflammation (e.g., asthma, atopic dermatitis)

  • Autoimmune diseases

  • Pruritus (chronic itching)

  Therapeutic exploration:

  • H3 antagonists: Pitolisant (approved for narcolepsy in EU)

  • H4 antagonists: In clinical trials for asthma, dermatitis, and IBD

  These receptors represent novel targets for drug development in neuroimmune cross-talk and precision therapy.

  Clinical Case Studies 

  ---

  🩺 Case Study 1: Bradykinin-Mediated Angioedema

  Case Summary:
  A 55-year-old male with long-standing hypertension was recently started on enalapril, an ACE inhibitor. Two weeks later, he presents to the emergency department with sudden swelling of the lips, tongue, and face, without urticaria or itching. He is afebrile, alert, and denies shortness of breath, although mild hoarseness is noted.

  Lab Tests:

  • CBC, renal and liver function – Normal

  • C1 esterase inhibitor – Normal

  • No eosinophilia

  Questions:

  1. What is the most likely cause of this patient’s angioedema?

  2. Which autacoid is implicated in the pathogenesis?

  3. Why is antihistamine therapy likely to be ineffective?

  4. What is the preferred treatment?

  Discussion:
  This is a classic case of ACE inhibitor-induced angioedema, mediated by excess bradykinin due to inhibition of its degradation. Bradykinin increases vascular permeability without involving histamine, which explains the lack of urticaria. Antihistamines and corticosteroids are generally ineffective. Treatment includes discontinuing the ACE inhibitor and administering a bradykinin B2 receptor antagonist such as icatibant. In severe cases, airway protection is critical.

  ---

  🩺 Case Study 2: Aspirin-Exacerbated Respiratory Disease (AERD)

  Case Summary:
  A 38-year-old woman with a history of asthma, nasal polyps, and chronic rhinosinusitis presents with worsening wheezing and nasal congestion. She reports that her symptoms significantly worsen after taking aspirin or ibuprofen. She has had several emergency visits following over-the-counter NSAID use.

  Lab/Imaging:

  • Sinus CT: Bilateral ethmoid sinus opacification

  • Spirometry: FEV1 65% predicted

  • Elevated eosinophils on CBC

  Questions:

  1. What is the likely diagnosis?

  2. Which autacoid pathway is overactivated in this patient?

  3. Why do NSAIDs worsen her symptoms?

  4. What pharmacologic alternatives are suitable?

  Discussion:
  This patient has Aspirin-Exacerbated Respiratory Disease (AERD), characterized by the “Samter's triad” of asthma, nasal polyps, and NSAID sensitivity. NSAIDs inhibit COX-1, shifting arachidonic acid metabolism toward the 5-LOX pathway, resulting in overproduction of leukotrienes (LTs), particularly LTC4, LTD4, and LTE4, which mediate bronchoconstriction and eosinophilic inflammation.

  Treatment includes:

  • Avoidance of NSAIDs

  • Leukotriene receptor antagonists (e.g., montelukast)

  • Corticosteroids

  • Biologics like dupilumab in severe cases

  ---

  🩺 Case Study 3: Carcinoid Syndrome and Serotonin Excess

  Case Summary:
  A 60-year-old female with a known neuroendocrine tumor of the ileum presents with recurrent diarrhea, flushing, abdominal cramping, and occasional wheezing. She reports episodic symptoms and has recently lost 5 kg unintentionally.

  Labs:

  • 24-hour urine 5-HIAA: Elevated

  • Serum chromogranin A: Elevated

  • CT scan: Hepatic metastases

  Questions:

  1. What is the diagnosis?

  2. Which autacoid is responsible for the systemic symptoms?

  3. Why is flushing observed in this condition?

  4. What is the pharmacologic treatment?

  Discussion:
  The patient has carcinoid syndrome, resulting from serotonin (5-HT) and other vasoactive substance secretion by metastatic neuroendocrine tumors, especially when liver metastases bypass hepatic metabolism.

  5-HT causes:

  • Increased GI motility → diarrhea

  • Vasodilation → flushing

  • Bronchospasm → wheezing

  Management:

  • Somatostatin analogs (e.g., octreotide) inhibit hormone release

  • Surgical resection if feasible

  • Targeted therapies for tumor control

  Monitoring includes 5-HIAA levels for disease progression.